FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174363935> ?p ?o ?g. }

• W3174363935 abstract "Background Riluzole is approved for the treatment of amyotrophic lateral sclerosis in most countries. Questions persist about its clinical utility because of high cost and modest efficacy. Objectives To examine the efficacy of riluzole in prolonging survival and in delaying the use of surrogates (tracheostomy and mechanical ventilation) to sustain survival, and to assess the effect of riluzole upon functional health. Search methods We searched the Cochrane Neuromuscular Disease Group Specialized Register (20 April 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 2), MEDLINE (1966 to April 2011), EMBASE (1980 to May 2011) and made enquiries of authors of trials, Aventis (manufacturer of riluzole) and other experts in the field. Selection criteria Types of studies: randomized controlled trials Types of participants: adults with a diagnosis of amyotrophic lateral sclerosis Types of interventions: treatment with riluzole or placebo Types of outcome measures: Primary: pooled hazard ratio of tracheostomy‐free survival over all time points with riluzole 100 mg. Secondary: per cent mortality with riluzole 50 mg, 100 mg and 200 mg; neurologic function, muscle strength and adverse events. Data collection and analysis One author performed data extraction and two other authors checked them. One author checked the data and entered them into the computer. The other authors verified the data entry. We obtained missing data from the trial authors whenever possible. Main results The four trials examining tracheostomy‐free survival included a total of 974 riluzole‐treated patients and 503 placebo‐treated patients. No new randomized controlled trials were found when we updated the searches for this update in 2011. The methodological quality was acceptable and three trials were easily comparable, although one trial (169 participants) included older patients in more advanced stages of amyotrophic lateral sclerosis and one (195 participants) had multiple primary endpoints. Riluzole 100 mg per day provided a benefit for the homogeneous group of patients in the first two trials (hazard ratio (HR) 0.80, 95% confidence internal (CI) 0.64 to 0.99, P= 0.042) and there was no evidence of heterogeneity (P = 0.33). When the third trial (which included older and more seriously affected patients) was added, there was evidence of heterogeneity (P < 0.0001) and the overall treatment effect was reduced but still significant (HR 0.84, 95% CI 0.698 to 0.997, P= 0.046). This represented a 9% gain in the probability of surviving one year (49% in the placebo and 58% in the riluzole group), and increased median survival from 11.8 to 14.8 months. There was a small beneficial effect on both bulbar and limb function, but not on muscle strength. A three‐fold increase in serum alanine transferase was more frequent in riluzole‐treated patients than controls (mean difference 2.62, 95% CI 1.59 to 4.31). Authors' conclusions Riluzole 100 mg daily is reasonably safe and probably prolongs median survival by about two to three months in patients with amyotrophic lateral sclerosis." @default.
• W3174363935 created "2021-07-05" @default.
• W3174363935 creator A5019416691 @default.
• W3174363935 creator A5032718531 @default.
• W3174363935 creator A5059617881 @default.
• W3174363935 creator A5061914662 @default.
• W3174363935 date "2012-03-14" @default.
• W3174363935 modified "2023-10-16" @default.
• W3174363935 title "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)" @default.
• W3174363935 cites W1554040650 @default.
• W3174363935 cites W1596759958 @default.
• W3174363935 cites W1964177214 @default.
• W3174363935 cites W1966263157 @default.
• W3174363935 cites W1986721894 @default.
• W3174363935 cites W2007949508 @default.
• W3174363935 cites W2020315918 @default.
• W3174363935 cites W2024309648 @default.
• W3174363935 cites W2024605213 @default.
• W3174363935 cites W2026487992 @default.
• W3174363935 cites W2027290785 @default.
• W3174363935 cites W2032618470 @default.
• W3174363935 cites W2032751921 @default.
• W3174363935 cites W2041199242 @default.
• W3174363935 cites W2046684326 @default.
• W3174363935 cites W2048558766 @default.
• W3174363935 cites W2049002531 @default.
• W3174363935 cites W2053693383 @default.
• W3174363935 cites W2074020222 @default.
• W3174363935 cites W2074842950 @default.
• W3174363935 cites W2075642745 @default.
• W3174363935 cites W2085165928 @default.
• W3174363935 cites W2088187475 @default.
• W3174363935 cites W2095011021 @default.
• W3174363935 cites W2109712577 @default.
• W3174363935 cites W2113542630 @default.
• W3174363935 cites W2119480471 @default.
• W3174363935 cites W2125472928 @default.
• W3174363935 cites W2130462384 @default.
• W3174363935 cites W2133300586 @default.
• W3174363935 cites W2134371523 @default.
• W3174363935 cites W2140860447 @default.
• W3174363935 cites W2166455544 @default.
• W3174363935 cites W2314689571 @default.
• W3174363935 cites W4206301525 @default.
• W3174363935 cites W4230986338 @default.
• W3174363935 cites W4234523356 @default.
• W3174363935 doi "https://doi.org/10.1002/14651858.cd001447.pub3" @default.
• W3174363935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/13129806" @default.
• W3174363935 hasPublicationYear "2012" @default.
• W3174363935 type Work @default.
• W3174363935 sameAs 3174363935 @default.
• W3174363935 citedByCount "413" @default.
• W3174363935 countsByYear W31743639352012 @default.
• W3174363935 countsByYear W31743639352013 @default.
• W3174363935 countsByYear W31743639352014 @default.
• W3174363935 countsByYear W31743639352015 @default.
• W3174363935 countsByYear W31743639352016 @default.
• W3174363935 countsByYear W31743639352017 @default.
• W3174363935 countsByYear W31743639352018 @default.
• W3174363935 countsByYear W31743639352019 @default.
• W3174363935 countsByYear W31743639352020 @default.
• W3174363935 countsByYear W31743639352021 @default.
• W3174363935 countsByYear W31743639352022 @default.
• W3174363935 countsByYear W31743639352023 @default.
• W3174363935 crossrefType "journal-article" @default.
• W3174363935 hasAuthorship W3174363935A5019416691 @default.
• W3174363935 hasAuthorship W3174363935A5032718531 @default.
• W3174363935 hasAuthorship W3174363935A5059617881 @default.
• W3174363935 hasAuthorship W3174363935A5061914662 @default.
• W3174363935 hasBestOaLocation W31743639352 @default.
• W3174363935 hasConcept C126322002 @default.
• W3174363935 hasConcept C142724271 @default.
• W3174363935 hasConcept C168563851 @default.
• W3174363935 hasConcept C1862650 @default.
• W3174363935 hasConcept C187960798 @default.
• W3174363935 hasConcept C197934379 @default.
• W3174363935 hasConcept C204787440 @default.
• W3174363935 hasConcept C207103383 @default.
• W3174363935 hasConcept C27081682 @default.
• W3174363935 hasConcept C2776356578 @default.
• W3174363935 hasConcept C2779134260 @default.
• W3174363935 hasConcept C2779319286 @default.
• W3174363935 hasConcept C2780596555 @default.
• W3174363935 hasConcept C44249647 @default.
• W3174363935 hasConcept C535046627 @default.
• W3174363935 hasConcept C71924100 @default.
• W3174363935 hasConcept C95190672 @default.
• W3174363935 hasConcept C99508421 @default.
• W3174363935 hasConceptScore W3174363935C126322002 @default.
• W3174363935 hasConceptScore W3174363935C142724271 @default.
• W3174363935 hasConceptScore W3174363935C168563851 @default.
• W3174363935 hasConceptScore W3174363935C1862650 @default.
• W3174363935 hasConceptScore W3174363935C187960798 @default.
• W3174363935 hasConceptScore W3174363935C197934379 @default.
• W3174363935 hasConceptScore W3174363935C204787440 @default.
• W3174363935 hasConceptScore W3174363935C207103383 @default.
• W3174363935 hasConceptScore W3174363935C27081682 @default.
• W3174363935 hasConceptScore W3174363935C2776356578 @default.
• W3174363935 hasConceptScore W3174363935C2779134260 @default.
• W3174363935 hasConceptScore W3174363935C2779319286 @default.

• next